The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.

Y Minami; T Shimamura; K Shah; T LaFramboise; K A Glatt; E Liniker; C L Borgman; H J Haringsma; W Feng; B A Weir

doi:10.1038/sj.onc.1210292

The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.

Identifier:nobleid.org/w1/20260515/463550A4

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/463550A4.svg?ark=w1%2F20260515%2F463550A4)](https://nobleid.org/work/w1/20260515/463550A4)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.

Identifier:nobleid.org/w1/20260515/463550A4

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/463550A4.svg?ark=w1%2F20260515%2F463550A4)](https://nobleid.org/work/w1/20260515/463550A4)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work